Clinical trial · Interventional
Fostering Oral Chemotherapy Understanding and Safety (FOCUS) Study
Fostering Oral Chemotherapy Understanding and Safety (FOCUS) Qualitative Study: Utilization of an Adherence Application
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to learn about the experiences of cancer patients during treatment utilizing a mobile app called EveryDose© to track prescribed oral treatment for cancer. Based on these experiences, the study team will decide on expanding this pilot study to evaluate other methods that may prove to be beneficial in supporting cancer patient's ability to take cancer medications as prescribed (another common phrase used for this is adherence to treatment).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| EveryDose Mobile Application | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- EveryDose Mobile Application Group
- description
- Participants in this group will use the EveryDose mobile application for up to 12 weeks.
- interventionNames
- Behavioral: EveryDose Mobile Application
Primary outcomes (3)
- measure
- Percentage of patients who agree to use the EveryDose application
- timeFrame
- up to 12 weeks
- description
- Percentage of patients who agree to use the EveryDose application
- measure
- EveryDose application adherence measured by percentage
- timeFrame
- up to 12 weeks
- description
- The percentage of weeks out of 12 week-period that the patient used the App (\> 50%)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Any sex/gender Able to provide written informed consent * Able to read/understand English or Spanish * Diagnosis of hematologic or solid tumor cancer diagnosis * Prescribed an oral anti-cancer drug as monotherapy treatment for the first time by their treating oncologist. * Internet access on a smartphone, tablet, or computer Exclusion Criteria: * Less than 18 years of age * Unable to provide written informed consent * Unable to read/understand English or Spanish * History of dementia or major psychiatric disease that would interfere with study participation * Prior treatment with an oral anti-cancer treatment * Participating in another clinical trial during the time of screening.
References
Publications (0)
Data not yet available